Results 1 to 10 of about 6,357 (207)

Efficacy and safety of darbepoetin alfa injection replacing epoetin alfa injection for the treatment of renal anemia in Chinese hemodialysis patients: A randomized, open‐label, parallel‐group, noninferiority phase III trial [PDF]

Chronic Diseases and Translational Medicine, 2022
Background This study was to explore the clinical efficacy and safety of darbepoetin alfa injection replacing epoetin alfa injection (recombinant human erythropoietin injection, rHuEPO) for the treatment of anemia associated with chronic kidney failure ...
Bicheng Liu, Nan Chen, Jinghong Zhao, Aiping Yin, Xiongfei Wu, Changying Xing, Gengru Jiang, Junzhou Fu, Mei Wang, Rong Wang, Jianying Niu, Ping Fu, Zhaohui Ni, Fanfan Hou, Jiuyang Zhao, Jing Chen, Yuqing Chen, Wei Shi, Jianghua Chen, Wenge Li, Gang Xu, Ling Zhong, Wenhu Liu, Guohua Ding, Yuichiro Kondo, Changhe Yue, Changlin Mei   +26 more
doaj   +2 more sources

Randomized Controlled Trial of Subcutaneous Epoetin Alfa-epbx Versus Epoetin Alfa in End-Stage Kidney Disease [PDF]

Kidney International Reports, 2019
Introduction: This double-blind, randomized controlled trial compared the safety and efficacy of subcutaneous epoetin alfa-epbx, an epoetin alfa biosimilar, with the reference product, epoetin alfa, in hemodialysis patients with end-stage kidney disease (
Steven Fishbane, Bruce S. Spinowitz, Wayne A. Wisemandle, Nancy E. Martin   +3 more
doaj   +2 more sources

An analysis of cost-saving in the German statutory health insurance system due to the introduction of epoetin alfa biosimilars in Germany [PDF]

Frontiers in Public Health
AimsEpoetin alfa, an erythropoiesis-stimulating agent, is the mainstay for treating severe anemia caused by kidney disease or induced by cancer-chemotherapy.
Ilka Raitner, Barbara Müller, Anjaly Vijayan, Lena Zimmermann, Peter Bramlage, Nils-Henning Ness, Markus Müller   +6 more
doaj   +2 more sources

Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure: A randomized, open‐label, parallel‐group, non‐inferiority Phase III trail [PDF]

Chronic Diseases and Translational Medicine, 2022
Background Erythropoietin is a glycoprotein that mainly regulates erythropoiesis. In patients with chronic renal failure with anemia, darbepoetin alfa can stimulate erythropoiesis, correct anemia, and maintain hemoglobin levels.
Nan Chen, Changying Xing, Jianying Niu, Bicheng Liu, Junzhou Fu, Jiuyang Zhao, Zhaohui Ni, Mei Wang, Wenhu Liu, Jinghong Zhao, Ling Zhong, Xiongfei Wu, Wenge Li, Yuqing Chen, Wei Shi, Jianghua Chen, Aiping Yin, Ping Fu, Rong Wang, Gengru Jiang, Fanfan Hou, Guohua Ding, Jing Chen, Gang Xu, Yuichiro Kondo, Yuliang Su, Changlin Mei   +26 more
doaj   +2 more sources

Economic Benefits of Switching From Intravenous to Subcutaneous Epoetin Alfa for the Management of Anemia in Hemodialysis Patients [PDF]

Canadian Journal of Kidney Health and Disease, 2020
Background: Erythropoiesis-stimulating agents including epoetin alfa have been a mainstay of anemia management in patients with chronic kidney disease.
Bhanu Prasad, Maryam Jafari, Julie Toppings, Linda Gross, Joanne Kappel, Flora Au   +5 more
doaj   +2 more sources

Long-term Safety of Epoetin Alfa-epbx for the Treatment of Anemia in ESKD: Pooled Analyses of Randomized and Open-label Studies [PDF]

Kidney Medicine, 2019
Rationale & Objective: Epoetin alfa-epbx is a biosimilar to the reference product, epoetin alfa. We compare the safety of epoetin alfa-epbx versus epoetin alfa based on a pooled analysis of findings from 2 randomized, double-blind, comparative clinical ...
Jay B. Wish, Marcelo G. Rocha, Nancy E. Martin, Christian Russel D. Reyes, Steven Fishbane, Mark T. Smith, George Nassar   +6 more
doaj   +2 more sources

Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study. [PDF]

Am J Hematol
ABSTRACT The COMMANDS trial established luspatercept as a first‐line treatment for anemia in transfusion‐dependent lower‐risk (LR) myelodysplastic syndromes (MDS). Here we report red blood cell (RBC) transfusion response analysis based on somatic mutations profile and disease risk for patients treated with luspatercept or epoetin alfa in the COMMANDS ...
Komrokji RS, Hayati S, Ugidos M, Garcia-Manero G, Della Porta MG, Zeidan AM, Santini V, Platzbecker U, Gandhi AK, Suragani RNVS.   +9 more
europepmc   +2 more sources

Population Pharmacodynamic Modeling of Epoetin Alfa in End‐Stage Renal Disease Patients Receiving Maintenance Treatment Using Bayesian Approach [PDF]

CPT: Pharmacometrics & Systems Pharmacology, 2020
The ability to control dosage regimens of erythropoiesis‐stimulating agents (ESAs) to maintain a desired hemoglobin (HGB) target is still elusive. We utilized a Bayesian approach and informative priors to characterize HGB profiles, using simulated drug ...
Ly Minh Nguyen, Calvin J. Meaney, Gauri G. Rao, Mandip Panesar, Wojciech Krzyzanski   +4 more
doaj   +2 more sources

Safety and Efficacy of Vadadustat Versus Darbepoetin Alfa for Chronic Kidney Disease-Related Anemia in Patients Receiving Dialysis by Baseline Erythropoiesis-Stimulating Agent Dose. [PDF]

Hemodial Int
ABSTRACT Introduction Erythropoiesis‐stimulating agents (ESAs) and iron supplementation are standard treatments for chronic kidney disease (CKD)–related anemia. Targeting higher hemoglobin values in CKD increases cardiovascular risk. Whether the increased risk is from higher ESA doses or higher hemoglobin levels is uncertain, but alternative therapies ...
Jardine A, Burke SK, Luo W, Minga T, Sarnak MJ, Winkelmayer WC, Agarwal R, Chertow GM, Eckardt KU, Koury MJ.   +9 more
europepmc   +2 more sources

Epoetin Alfa: A Cause of Coronary Artery Thrombosis [PDF]

Case Reports in Cardiology, 2017
Introduction. Epoetin alfa is an erythrocyte-stimulating factor. We here present a case of an anemic patient, who was given epogen before a coronary artery bypass (CABG) surgery and developed periprocedural myocardial infarction.
Muhammad Umer Siddiqui, Yelena Galumyan, James Klein, Zunaira Naeem, Aron Schwarcz   +4 more
doaj   +2 more sources